Latest Immutep News & Updates

See the latest news and media coverage for Immutep. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Immutep

Biotechnology company developing LAG-3 immunotherapies

immutep.com
Headquarters
Sydney, Australia
Company type
Public company
Number of employees
10–60
Industry
Pharmaceuticals

Last updated

Latest news about Immutep

In short: Immutep discontinued its Phase III TACTI-004 lung cancer trial due to futility and shifted focus to head and neck cancer and sarcoma.

Company announcements

Immutep

Immutep reports positive mature overall survival data from INSIGHT-003

Mature mOS of 30.9 months in 1L non-squamous NSCLC patients, including those with TPS<50%. TACTI-004 update with root cause analysis ongoing.

Unlock all announcements with a

Media coverage

RTTNews

Immutep Limited Full Year Loss Increases

Immutep Limited ( IMMP) reported Loss for its full year of -A$79.30 million The company's bottom line totaled -A$79.30 million, or -A$0.0539 per share. This...

Kalkine

Immutep's Eftilagimod Alfa Quality of Life Data Accepted for ESMO Congress 2026 Presentation

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a late-stage immunotherapy company, has announced that an abstract evaluating health-related quality of life outcomes from its investigator-initiated EFTISARC-NEO...

Unlock all articles with a

Never miss news about Immutep

Track Immutep and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Immutep competitors & trending companies

Browse news for competitors to Immutep and other trending companies.